Patents Examined by San Ming R. Hui
  • Patent number: 11992490
    Abstract: The present application provides methods of treating a disease selected from cutaneous lupus erythematosus (CLE) and Lichen planus (LP) in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a JAK1 selective inhibitor, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: May 28, 2024
    Assignee: Incyte Corporation
    Inventors: Paul Smith, Jörg Wenzel
  • Patent number: 11986478
    Abstract: The subject invention pertains to compounds and methods of using said compounds to target the multi-functional papain-like protease (PLpro) domain of the viral Nsp3, specifically F0213, F0326, and F0393 that can have broad anti-coronavirus activity, including SARS-CoV-2, MERS-CoV, and coronaviruses hCoV-229E and hCoV-OC43. F0213, F0326, and F0393 can possess a dual therapeutic functionality that suppress CoV replication via blocking viral polyprotein cleavage, as well as promote antiviral immunity by antagonizing the PLpro deubiquitinase activity.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: May 21, 2024
    Assignees: Versitech Limited, Centre for Virology, Vaccinology and Therapeutics Limited
    Inventors: Shuofeng Yuan, Fuk Woo Jasper Chan, Kwok Yung Yuen
  • Patent number: 11980625
    Abstract: The disclosure to methods for treating tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutically acceptable pregnenolone neurosteroid, such as ganaxolone, to reduce one or more symptoms of tuberous sclerosis complex or tuberous sclerosis complex-related epilepsy.
    Type: Grant
    Filed: April 26, 2023
    Date of Patent: May 14, 2024
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Alex Aimetti, Joseph Hulihan, Scott Braunstein
  • Patent number: 11980621
    Abstract: The invention provides methods of treating endometriosis in a patient by administration of a gonadotropin-releasing hormone (GnRH) antagonist, for instance, according to dosing regimens predicated on the patient's level of anti-Müllerian hormone (AMH) or ?17-estradiol (E2).
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 14, 2024
    Assignee: Kissei Pharmaceutical Co., Ltd.
    Inventors: Ernest Loumaye, Jean-Pierre Gotteland
  • Patent number: 11969434
    Abstract: Disclosed is a method and an oral composition for treating CNS disorders. An embodiment of the invention comprises orally administering an allopregnanolone containing composition to a subject having a CNS disorder. Exemplary CNS disorders include sleep disorders, mood disorders, dysthymic disorders, bipolar disorders, anxiety disorders, stress disorders, compulsive disorders, schizophrenia spectrum disorders, convulsive disorders, memory disorders, cognition disorders, movement disorders, personality disorders, autism spectrum disorders, substance abuse disorders, dementia, pain, traumatic brain injury (TBI), vascular disease, withdrawal syndrome, and tinnitus. The composition and methods disclosed herein exhibit effective oral absorption/bioavailability.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: April 30, 2024
    Inventors: Jonathan Ogle, Benjamin J. Bruno, Kongnara Papangkorn, Samuel Akapo, Joel Frank, Nachiappan Chidambaram, Mahesh V. Patel
  • Patent number: 11970462
    Abstract: An ethyl 3-[4,4-bis(4-chlorophenyl)-2,5-dioxoimidazolidin-1-yl]propanoate compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: January 3, 2024
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Mohamed Gouda, Hany Mohamed Abd El-Lateef Ahmed, Tamer Mohamed Abdelghani Ibrahim, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11957670
    Abstract: The present disclosure relates to a method of treating or preventing mitochondrial diseases by administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione or a salt thereof to a subject in need thereof. The disclosure also relates to 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for use in a pharmaceutical composition or in the manufacture of a medicament for the treatment or prevention of a mitochondrial disease.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 16, 2024
    Assignee: Minoryx Therapeutics S.L.
    Inventors: Marc Martinell Pedemonte, Maria Pilar Pizcueta Lalanza, Laura Pilar Rodríguez Pascau
  • Patent number: 11951103
    Abstract: The present invention relates to a therapeutic agent for an ophthalmic disease comprising a vascular endothelial growth factor (VEGF) receptor inhibitor or an epidermal growth factor (EGF) receptor inhibitor in a nanoparticle form, having a property to be retained in a posterior eye tissue when systemically administered.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: April 9, 2024
    Assignee: KYOWA KIRIN CO., LTD.
    Inventors: Hiroki Haniuda, Sachiko Enokizono, Tomoyuki Nakazato, Takuya Tokuda, Norie Fujiki
  • Patent number: 11951107
    Abstract: Provided herein is a pharmaceutical composition comprising (i) a phosphodiesterase inhibitor or an adenosine receptor antagonist, (ii) a calcium channel blocker, (iii) a histamine H1-receptor agonist, a histamine H2-receptor agonist, or a histamine H3-receptor antagonist, and (iv) a ?2-adrenoreceptor agonist; wherein at least one of two or more active pharmaceutical compounds is deuterium enriched. Also provided herein is a pharmaceutical composition comprising at least one of two or more deuterated compounds which increase pharmacokinetic half-life (increasing the duration of action) and reduce side effects by allowing for reduction of the dose levels. A method of use thereof pharmaceutical composition for treating, preventing, or ameliorating a cardiovascular disease.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: April 9, 2024
    Assignee: CARDIX Therapeutics, LLC
    Inventors: Jin Jean Wang, Gerald J. Yakatan
  • Patent number: 11951112
    Abstract: A method of treating late-onset congenital adrenal hyperplasia due to 21-hydroxylase deficiency by individually tailored glucocorticoid regimen is provided. The method can be practically used to treat adult humans who suffer from symptoms of late-onset 21-hydroxylase deficiency caused by the mutation of the CYP21A2 gene. The method consists of daily intake of two glucocorticoids: dexamethasone in evenings and hydrocortisone in the mornings, in doses specially selected for each patient based on the analysis and monitoring of 17?-hydroxyprogesterone, progesterone, sex hormone-binding globulin, adre-nocorticotropic hormone, fasting glucose, hemoglobin A1C, C-Peptide, the Parathyroid Hormone intact, blood pressure, body weight. During glucocorticoid intake, in order to counterbalance ad-verse reactions, the patient should also take supplements of potassium, calcium, vitamin D and vitamin K.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: April 9, 2024
    Inventor: Maxim Masiutin
  • Patent number: 11944633
    Abstract: An oral pharmaceutical composition is provided that can comprise a rho kinase inhibitor, for example, fasudil, a pharmaceutically acceptable salt thereof, a hydrate thereof, a prodrug thereof, a substituted derivative thereof, or a metabolite thereof, or any combination thereof, the rho kinase inhibitor having a bitter taste; and an ion exchange resin. The ion exchange resin can partially or fully mask the bitter taste of the rho kinase inhibitor, making the composition more palatable. The composition can comprise a solid dosage form, and/or a liquid dosage form. The solid dosage form can comprise a powder, granules, a tablet, or a capsule, or any combination thereof. The composition can be present, for example, in a unit dose, in an amount sufficient to treat a neurodegenerative disease. A method of treating the neurodegenerative disease with the oral pharmaceutical composition is provided. The method can ameliorate a symptom of a neurodegenerative disease.
    Type: Grant
    Filed: February 17, 2023
    Date of Patent: April 2, 2024
    Assignee: Woolsey Pharmaceuticals, Inc.
    Inventors: Qicai Liu, Hemant N. Joshi, Thomas MacAllister
  • Patent number: 11932593
    Abstract: An 8-(3-bromobenzylideneamino)naphthalene-1,3-disulfonic acid compound, its synthesis, and its use as an antioxidant agent.
    Type: Grant
    Filed: October 31, 2023
    Date of Patent: March 19, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11911389
    Abstract: Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H1-receptor agonist, a histamine H2-receptor agonist, a histamine H3-receptor antagonist, or a ?2-adrenoreceptor agonist.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: February 27, 2024
    Assignee: Cardix Therapeutics LLC
    Inventors: Jin Jean Wang, Gerald J. Yakatan, Ting N. Lin, Jing H. Gao
  • Patent number: 11911398
    Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: February 27, 2024
    Assignee: OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
  • Patent number: 11896580
    Abstract: The disclosure discloses a composition containing melatonin as an effective ingredient, and its application in improving DHI production performance and improving milk quality. The composition containing melatonin as an effective ingredient according to the present disclosure can significantly reduce the somatic cell count in milk and improve milk quality. Under the conditions of different seasons, ages, and lactation periods, the administration of the composition containing melatonin as an active ingredient according to the present disclosure can significantly reduce the somatic cell score of cow milk (p<0.01), increase the protein content and lactose content in milk, and meanwhile reduce the fat content and urea nitrogen content in milk. In summary, the composition containing melatonin as an effective ingredient according to the present disclosure can improve the quality of milk and increase the efficiency of dairy cow breeding.
    Type: Grant
    Filed: October 15, 2021
    Date of Patent: February 13, 2024
    Assignee: CHINA AGRICULTURAL UNIVERSITY
    Inventors: Guoshi Liu, Hao Wu, Yongqiang Lu, Lu Zhang, Hui Ma, Yi Chang, Qiaoxiang Liu, Songyang Yao, Pengyun Ji
  • Patent number: 11890266
    Abstract: Pharmaceutical ocular compositions include levodopa, an antioxidant and an aqueous carrier. A wide selection of antioxidants can be included in the compositions, such as ascorbic acid, phenolic acids, sorbic acid, sodium bisulfite, sodium metabisulfite, acetyl cysteine, sodium thiosulfate, ethylene diamine tetraacetic acid, sodium nitrite, ascorbyl stearate, ascorbyl palmitate, alpha-thioglycerol, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol or vitamin E, tocopherol acetate, dibutylhydroxytoluene, soybean lecithin, sodium thioglycolate, butylhydroxyanisole, propyl gallate, uric acid, melatonin, and thiourea, as well as salts and combinations of these antioxidants.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 6, 2024
    Assignee: UNIVERSITY OF CANBERRA
    Inventor: Regan Scott Ashby
  • Patent number: 11883404
    Abstract: It is intended to provide a novel method for treating a cancer using an FGFR inhibitor that exhibits a remarkably excellent antitumor effect and has fewer side effects. The present invention provides a combination preparation for the treatment of a malignant tumor comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof, and one or more additional compound(s) having an antitumor effect or pharmaceutically acceptable salt(s) thereof, and a pharmaceutical composition comprising both the active ingredients. The present invention also provides an antitumor effect enhancer, an antitumor agent, a kit for malignant tumor treatment, etc. comprising a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 30, 2024
    Assignee: Taiho Pharmaceuticals Co., Ltd.
    Inventors: Akihiro Miura, Hiroshi Sootome, Junya Iwasaki
  • Patent number: 11878974
    Abstract: Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
    Type: Grant
    Filed: January 14, 2021
    Date of Patent: January 23, 2024
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 11865091
    Abstract: The invention relates to an agent having immunomodulatory properties for the prevention and/or treatment of autoimmune diseases, said agent comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or C1-C8 alkyl esters, and their use as immunomodulatory agents for use in prevention and/or treatment of autoimmune related diseases and immune-mediated chronic inflammatory diseases, and dietary supplements with immunomodulating effect comprising one or more C3-C8 carboxylic acids and their physiologically acceptable salts and/or esters comprising C1-C8 alkyl alcohols.
    Type: Grant
    Filed: June 3, 2020
    Date of Patent: January 9, 2024
    Assignee: Flexopharm Brain GMBH & Co. KG
    Inventors: Ralf Gold, Aiden Haghikia, Ralf Linker
  • Patent number: 11856954
    Abstract: An insecticidal composition is disclosed that contains two active ingredients, which are transfluthrin and imiprothrin. The insecticide composition may further contain at least one of a solvent and a propellant. The weight percentage of each of the active ingredients may be about 0.01% to 0.5% by weight.
    Type: Grant
    Filed: April 7, 2022
    Date of Patent: January 2, 2024
    Assignee: S.C. JOHNSON & SON, INC.
    Inventor: Kristina Marie Knesting